All In Biotech

Drug Trial Radar · NCT07116733

Desflurane vs. Propofol for Cardiac Anesthesia

Desflurane vs. Propofol for Cardiac Anesthesia: Impact on Developing Major Cardiac Events in Patients Undergoing CABG Procedure

Last checked: Nov 19, 2026Latest source record: Nov 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 3,560 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

3,560

Planned (sponsor's estimate)

Start

Oct 20, 2025

Primary completion

Dec 31, 2028

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Xijing HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To investigate whether the inhaled anesthetic desflurane, compared with propofol, exerts cardioprotective effects and reduces the incidence of severe postoperative major cardiac events in patients undergoing coronary artery bypass graft (CABG) surgery.

Conditions

  • Cardiac Surgery
  • Coronary Artery Bypass Grafting

Interventions

  • Desflurane groupDrug

    After routine induction, maintain anesthesia with inhaled desflurane , adjusting concentration as needed to sustain 0.5-2 MAC . To maximize the cardioprotective effects of inhaled anesthetics, adhere to this intraoperative strategy: Maintain ≥1 MAC continuous desflurane for ≥30 minutes ; For on-pump CABG , discontinue desflurane 15 minutes before initiating cardiopulmonary bypass (CPB) ; If intraoperative desflurane cessation is required, implement a wash-in/wash-out strategy (recommended but non-mandatory): Perform 3 alternating cycles of: Wash-in : ≥10 minutes of desflurane at ≥0.5 MAC, Wash-out : ≥10 minutes of complete cessation of inhaled anesthetics. Propofol is strictly prohibited for anesthesia maintenance throughout the procedure , except during CPB.

  • Propofol groupDrug

    Administer total intravenous anesthesia (TIVA) using propofol infusion at 3-8 mg/kg/h . No inhaled anesthetics are permitted for maintenance. This may be delivered via:target-controlled infusion (TCI) systems, or manual adjustment of intravenous infusion rates.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite outcome of death and major cardiac eventsTime frame: within 30 days after operation

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Daping Hospital, Army Medical University

    Chongqing, China · Not yet recruiting

  • Changhai Hospital

    Shanghai, China · Recruiting

  • Zhongshan Hospital, Fudan University

    Shanghai, China · Not yet recruiting

  • Fuzhou University Affiliated Provincial Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • Cangzhou People's Hospital

    Cangzhou, Hebei, China · Not yet recruiting

  • Hebei General Hospital

    Shijiazhuang, Hebei, China · Not yet recruiting

  • The First Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Not yet recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Not yet recruiting

  • Wuhan Asia Heart Hospital

    Wuhan, Hubei, China · Not yet recruiting

  • Jiangsu Province Hospital

    Nanjin, Jiangsu, China · Not yet recruiting

  • Xijing Hospital

    Xi'an, Shaanxi, China · Recruiting

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China · Not yet recruiting

  • Tianjin Chest Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • Ningbo No.2 Hospital

    Ningbo, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.